In Vitro Diagnostics (IVD) include reagents, instruments, and systems intended for use in the diagnosis of disease or other conditions, including the determination of the state of health, in order to treat or prevent disease. The reagents, instruments and systems are used in the collection, preparation, and examination of specimens taken from the human body. This includes Cardiac Disease, Hematological Disorders, Hormonal Disorders, Metabolic Disorder, Infectious Disease, IVD Analyzers, Oncology and Reproductive Health Diagnostics. Epidermal Growth Factor Receptor gene (EGFR) Tests are carried out to detect mutations within this receptor gene in Non-Small Cell Lung Cancer (NSCLC) tumor cells; the outcome of which may determine if EGFR-targeted tyrosine kinase inhibitors such as gefitinib and erlotinib may be beneficial for treating NSCLC. GlobalData uses proprietary data and analytics to provide a comprehensive report on the egfr tests devices market, including market shares of different players within New Zealand. Buy the latest report here.
In 2023, GlobalData’s Market Model methodology determined that the leading player in the egfr tests market in New Zealand was Thermo Fisher Scientific followed by Qiagen, F. Hoffmann-La Roche, Abbott Laboratories and Agilent Technologies.
The EGFR Tests includes EGFR Immunohistochemistry Tests, EGFR Nucleic Acid Amplification Tests (NAATs), EGFR Sanger Sequencing Tests, and EGFR Other Tests which include In Situ Hybridisation (ISH) and Mass Array.
The value of the egfr tests devices market within New Zealand was expected to be over $0.02m in 2023.
For the latest complete market share analysis of egfr tests device market in New Zealand, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.